This novel delivery method, applied to the inside of the cheek, offers a streamlined two-hour in-clinic treatment. Atai plans to begin a Phase 2 study by the end of 2024 to evaluate VLS-01's safety, ...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...
Exploring how emotional injuries manifest, the ways they disrupt daily life, and the legal recourse available to victims can guide individuals affected emotionally through negligence to take steps ...
The Annual International Conference on ADHD provides continuing education credits to physicians and nurses, mental health professionals, and ADHD and life coaches. For more information and to register ...